drugset / Trial / NCT04545710
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
Phase 2
Active not recruiting
18 enrolled
University of California, San Diego
Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
Lung cancer is the leading cause of cancer deaths. Advances in the systemic treatment of non-small cell lung cancer (NSCLC) have increased survival in metastatic EGFR-mutated NSCLC. However resistance to therapy can develop.
Timeline
- Start
- 2020-11-21
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | — |
| Subject | Osimertinib | Small molecule | 80 mg | — |